Potent Anti-Influenza Activity of Cyanovirin-N and Interactions with Viral Hemagglutinin

ABSTRACT The novel antiviral protein cyanovirin-N (CV-N) was initially discovered based on its potent activity against the human immunodeficiency virus (HIV). Subsequent studies identified the HIV envelope glycoproteins gp120 and gp41 as molecular targets of CV-N. More recently, mechanistic studies have shown that certain high-mannose oligosaccharides (oligomannose-8 and oligomannose-9) found on the HIV envelope glycoproteins comprise the specific sites to which CV-N binds. Such selective, carbohydrate-dependent interactions may account, at least in part, for the unusual and unexpected spectrum of antiviral activity of CV-N described herein. We screened CV-N against a broad range of respiratory and enteric viruses, as well as flaviviruses and herpesviruses. CV-N was inactive against rhinoviruses, human parainfluenza virus, respiratory syncytial virus, and enteric viruses but was moderately active against some herpesvirus and hepatitis virus (bovine viral diarrhea virus) strains (50% effective concentration [EC50] = ∼1 μg/ml) while inactive against others. Remarkably, however, CV-N and related homologs showed highly potent antiviral activity against almost all strains of influenza A and B virus, including clinical isolates and a neuraminidase inhibitor-resistant strain (EC50 = 0.004 to 0.04 μg/ml). When influenza virus particles were pretreated with CV-N, viral titers were lowered significantly (>1,000-fold). Further studies identified influenza virus hemagglutinin as a target for CV-N, showed that antiviral activity and hemagglutinin binding were correlated, and indicated that CV-N′s interactions with hemagglutinin involved oligosaccharides. These results further reveal new potential avenues for antiviral therapeutics and prophylaxis targeting specific oligosaccharide-comprised sites on certain enveloped viruses, including HIV, influenza virus, and possibly others.

[1]  H. Klenk,et al.  Intraepidemic variants of influenza virus H3 hemagglutinin differing in the number of carbohydrate side chains , 2005, Archives of Virology.

[2]  Mike Bray,et al.  Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. , 2003, Antiviral research.

[3]  A. Gronenborn,et al.  Functional homologs of cyanovirin-N amenable to mass production in prokaryotic and eukaryotic hosts. , 2002, Protein expression and purification.

[4]  A. Gronenborn,et al.  Multisite and multivalent binding between cyanovirin-N and branched oligomannosides: calorimetric and NMR characterization. , 2002, Chemistry & biology.

[5]  Alexander Wlodawer,et al.  Structures of the Complexes of a Potent Anti-HIV Protein Cyanovirin-N and High Mannose Oligosaccharides* , 2002, The Journal of Biological Chemistry.

[6]  D. Smee,et al.  Characterization of an influenza A (H3N2) virus resistant to the cyclopentane neuraminidase inhibitor RWJ-270201. , 2001, Antiviral research.

[7]  C. Bewley,et al.  Solution Structure of a Cyanovirin-N:Manα1-2Manα Complex , 2001 .

[8]  Y. Muraki,et al.  Antigenic structure of the haemagglutinin of human influenza A/H2N2 virus. , 2001, The Journal of general virology.

[9]  M. Boyd,et al.  Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner. , 2001, Molecular pharmacology.

[10]  M. Boyd,et al.  Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins. , 2001, The Journal of pharmacology and experimental therapeutics.

[11]  C. Bewley Solution structure of a cyanovirin-N:Man alpha 1-2Man alpha complex: structural basis for high-affinity carbohydrate-mediated binding to gp120. , 2001, Structure.

[12]  I. Capua,et al.  Changes in the haemagglutinin and the neuraminidase genes prior to the emergence of highly pathogenic H7N1 avian influenza viruses in Italy , 2001, Archives of Virology.

[13]  M. Boyd,et al.  Analysis of the interaction between the HIV-inactivating protein cyanovirin-N and soluble forms of the envelope glycoproteins gp120 and gp41. , 2000, Molecular pharmacology.

[14]  K. Zaner,et al.  Mechanism of binding of surfactant protein D to influenza A viruses: importance of binding to haemagglutinin to antiviral activity. , 2000, The Biochemical journal.

[15]  J. McKimm-Breschkin,et al.  Resistance of influenza viruses to neuraminidase inhibitors--a review. , 2000, Antiviral research.

[16]  M. Boyd,et al.  Multiple Antiviral Activities of Cyanovirin-N: Blocking of Human Immunodeficiency Virus Type 1 gp120 Interaction with CD4 and Coreceptor and Inhibition of Diverse Enveloped Viruses , 2000, Journal of Virology.

[17]  Laurent Kaiser,et al.  Influenza virus neuraminidase inhibitors , 2000, The Lancet.

[18]  L. Pannell,et al.  Recombinant production of cyanovirin-N, a potent human immunodeficiency virus-inactivating protein derived from a cultured cyanobacterium. , 1998, Protein expression and purification.

[19]  L K Pannell,et al.  Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development , 1997, Antimicrobial agents and chemotherapy.

[20]  P. Reading,et al.  Changes in the hemagglutinin molecule of influenza type A (H3N2) virus associated with increased virulence for mice , 1997, Archives of Virology.

[21]  N. Kato,et al.  Antigenicity of hepatitis C virus envelope proteins expressed in Chinese hamster ovary cells. , 1996, Vaccine.

[22]  W. A. Harrison,et al.  Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide , 1995, Antimicrobial agents and chemotherapy.

[23]  H. Asada,et al.  Analysis of human herpesvirus 6 glycoproteins recognized by monoclonal antibody OHV1. , 1992, The Journal of general virology.

[24]  D. Jackson,et al.  Bovine and mouse serum beta inhibitors of influenza A viruses are mannose-binding lectins. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[25]  D. J. Arora,et al.  Concentration and purification of influenza virus from allantoic fluid. , 1985, Analytical biochemistry.

[26]  G. Campadelli-Fiume,et al.  Processing of N-linked oligosaccharides from precursor- to mature-form herpes simplex virus type 1 glycoprotein gC , 1984, Journal of virology.

[27]  D. Thorley-Lawson,et al.  Synthesis and processing of the three major envelope glycoproteins of Epstein-Barr virus , 1983, Journal of virology.

[28]  J. Yewdell,et al.  The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype) , 1982, Cell.

[29]  M. Nakanishi,et al.  Carbohydrate structures of HVJ (Sendai virus) glycoproteins. , 1981, The Journal of biological chemistry.

[30]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[31]  N. Finter Dye Uptake Methods for Assessing Viral Cytopathogenicity and their Application to Interferon Assays , 1969 .

[32]  L. Reed,et al.  A SIMPLE METHOD OF ESTIMATING FIFTY PER CENT ENDPOINTS , 1938 .

[33]  M. Maksimovic,et al.  Solution , 1902, The Mathematical Gazette.